Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(67%)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Active, not recruiting1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
0.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

active_not_recruiting133%
recruiting133%
terminated133%

Recent Activity

2 active trials
Showing 3 of 3
active_not_recruitingnot_applicable

Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

NCT04653740
terminated

Discovering Cancer Risks From Environmental Contaminants and Maternal/Child Health

NCT05746169
recruiting

Natural History Study for DNA Repair Disorders

NCT05484570

Clinical Trials (3)

Showing 3 of 3 trials
NCT04653740Not Applicable

Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

Active Not Recruiting
NCT05746169

Discovering Cancer Risks From Environmental Contaminants and Maternal/Child Health

Terminated
NCT05484570

Natural History Study for DNA Repair Disorders

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3